Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Nanoparticle-Based Drug Targeting for the Treatment of Cardiovascular Disorders
share announcement

Nanoparticle-Based Drug Targeting for the Treatment of Cardiovascular Disorders

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".

Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 1897

Special Issue Editors

Dr. Eliana Hiromi Akamine

E-Mail Website
Guest Editor
Departamento de Farmacologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil
Interests: vascular biology; cardiovascular pharmacology; aging; obesity
Dr. Stephen Fernandes Rodrigues

E-Mail Website
Guest Editor
Departamento de Farmacologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil
Interests: vascular nanopharmacology; microcirculation; nanodrugs

Special Issue Information

Dear Colleagues,

Cardiovascular diseases represent a group of heart and circulatory disease conditions, which include coronary heart disease, subclinical atherosclerosis, heart failure, stroke, rhythm disorders, venous disease, peripheral vascular disease, and various other conditions. Despite the advancements in the invasive interventions and pharmacological therapies, cardiovascular diseases remain the leading cause of deaths worldwide and account for a high morbidity rate. In this context, nanoparticles have already been marketed to treat a few diseases, such as some forms of cancer, and they are soon set to be approved for use in the treatment of other conditions, such as cardiovascular disease. Among the advantages of nanoparticles are their tiny size, which allows them to promptly cross membrane barriers. In addition, nanoparticles can be filled concomitantly with one or more drugs and contain antibodies or peptides that direct them to a particular cell type or tissue. Thus, this Special Issue invites the submission of manuscripts that address nanoparticle-based drug targeting for the treatment of cardiovascular diseases. Potential topics include, but are not limited to, the reduction in or prevention of atherosclerotic lesions, thrombi formation, and vascular inflammation and dysfunction. Manuscripts that address reductions in cardiovascular risk factors (cholesterol, blood pressure and glucose control) are also welcome. Original research and review articles are requested that describe innovative nanoparticle- and nanocarrier-based drug delivery, the new use of known nanoparticles, and mechanisms of action underlying the cardiovascular effects of the nanoparticles.

Dr. Eliana Hiromi Akamine
Dr. Stephen Fernandes Rodrigues
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanoparticles
  • cardiovascular diseases
  • atherosclerosis
  • thrombosis
  • ischemia-reperfusion
  • stroke
  • endothelium
  • vascular smooth muscle cells
  • perivascular adipose tissue
  • inflammation
  • oxidative stress

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

28 pages, 13080 KiB  
Article
Nanostructured Lipid Carriers to Enhance the Bioavailability and Solubility of Ranolazine: Statistical Optimization and Pharmacological Evaluations
by Aziz Unnisa, Ananda K. Chettupalli, Reem S. Alazragi, Walla Alelwani, Azzah M. Bannunah, Jameel Barnawi, Padmanabha R. Amarachinta, Suresh B. Jandrajupalli, Badria A. Elamine, Omkalthoum A. Mohamed and Talib Hussain
Pharmaceuticals 2023, 16(8), 1151; https://doi.org/10.3390/ph16081151 - 14 Aug 2023
Cited by 4 | Viewed by 1559
Abstract
Chronic stable angina pectoris is the primary indication for ranolazine (RZ), an anti-anginal drug. The drug has an anti-ischemic action that is unaffected by either blood pressure or heart rate. Due to the first-pass effect, the drug has a reduced bioavailability of 35 [...] Read more.
Chronic stable angina pectoris is the primary indication for ranolazine (RZ), an anti-anginal drug. The drug has an anti-ischemic action that is unaffected by either blood pressure or heart rate. Due to the first-pass effect, the drug has a reduced bioavailability of 35 to 50%. The study emphasized developing a novel transdermal drug delivery system of nanostructured lipid carriers (NLCs) for delivering RZ. Many pharmaceutical companies employ lipid nanoparticles as biocompatible carriers for medicinal, cosmetic, and biochemical uses. These carriers are appropriate for many applications, such as topical, transdermal, parenteral, pulmonary, and oral administration, because of the large variety of lipids and surfactants that are readily available for manufacturing. RZ NLCs were made using high-pressure homogenization. Statistical analysis was utilized to find the best formula by varying the concentrations of Precirol ATO 5 (X1), oleic acid (X2), and Tween 80 (X3). Variables such as entrapment effectiveness (EE) (Y1), particle size (Y2), polydispersity index (PDI) (Y3), and zeta potential (Y4) were tested. A variety of tests were performed on the new formulation to ascertain how well it would be absorbed in the body. These tests included in vivo absorption studies, skin permeability assessments, in vitro drug release assessments, and physicochemical analyses. The particle size of RZ-NLCs was shown to be very small (118.4 ± 5.94 nm), with improved EE (88.39 ± 3.1%) and low ZP and PDI (−41.91 ± 0.38 and 0.118 ± 0.028). SEM and TEM analysis confirmed the structure of the NLCs and showed a smooth, spherical surface. Improved RZ-NLCs were used to create NLC gel, which was then tested for elasticity both physically and rheologically. The formulation’s elasticity was investigated. Optimized RZ-NLCs and NLCG were found to have transdermal fluxes of 48.369 g/cm2/h and 38.383 g/cm2/h, respectively. These results showed that the transdermal delivery of RZ distribution through NLC’s transdermal gel had more significant potential. According to in vivo experiments, the drug’s bioavailability in Wistar rats increased when it was delivered through NLCs. The findings demonstrated that NLCs loaded with RZ successfully transported the RZ to the designated site with no interruptions and that a quadratic connection existed between the independent and dependent variables. Full article
(This article belongs to the Special Issue Nanoparticle-Based Drug Targeting for the Treatment of Cardiovascular Disorders)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop